New drug combo aims to shrink aggressive prostate cancer before surgery
NCT ID NCT07476677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called darolutamide, with or without hormone therapy (ADT), given before surgery for high-risk localized prostate cancer. Sixty men will be split into two groups: one gets darolutamide alone, the other gets darolutamide plus ADT for 3-6 months before robotic surgery. The goal is to see if the treatment reduces cancer enough to improve surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darolutamide (a drug that blocks male hormones) with or without ADT (androgen deprivation therapy)
What this could lead to
If successful, this could lead to a new treatment option that shrinks high-risk prostate cancer before surgery, potentially improving outcomes.
What could go wrong
This is a small, early-phase study (60 people) with no results yet. The treatment may not work better than current options, and ADT can cause side effects like hot flashes and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 101205, China
Contact